Entities / Company
Veracyte (United States).
company in South San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 44
What's happening
Gone quiet
No new reports in 90+ days-
The removal of Triumph Group impacted market sentiment on July 26, 2025, affecting companies like Veracyte.Some support1 report1 development inside
-
Triumph Group was replaced in the index on July 25, 2025, while Veracyte joined, amid acquisition plans by Warburg Pincus and Berkshire Partners.Some support1 report
-
Veracyte presented Afirma GRID studies at the Endocrine Society Annual Meeting, which was held in San Francisco on July 9, 2025.Speculative1 report
-
Veracyte and Transmedics operate within the same molecular diagnostic industry.Some support1 report1 development inside
-
Helix and Veracyte announced a partnership on August 7, 2025, to expand access to genomic insights.Some support1 report
-
Marc Stapley was appointed as the chief executive officer of Veracyte on August 7, 2025.Some support2 reports
-
Veracyte reported that its earnings and revenue beat consensus estimates on August 12, 2025.Some support1 report
-
Zacks highlighted Veracyte as a strong momentum stock on August 24, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Veracyte (United States) this week
News at the entities that move Veracyte (United States) most-
San Francisco Shared contextSan Diego's PCI is ranked below Los Angeles, San Francisco, and Long Beach, while La Jolla seeks to detach from San Diego.Moves Veracyte (United States)
Connections
The 2 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
San Francisco Shared context
Veracyte is headquartered in San Francisco, California.
-
Iglesia de San Francisco Shared context
A and B share the geographic context of San Francisco.
History
Events by the month they beganJune 2026
9 events- Veracyte, a company headquartered in San Francisco, CA, offers diagnostic tests through central laboratories in the United States.
- The removal of Triumph Group impacted market sentiment on July 26, 2025, affecting companies like Veracyte.
- Triumph Group was replaced in the index on July 25, 2025, while Veracyte joined, amid acquisition plans by Warburg Pincus and Berkshire Partners.
- Veracyte presented Afirma GRID studies at the Endocrine Society Annual Meeting, which was held in San Francisco on July 9, 2025.
- Veracyte and Transmedics operate within the same molecular diagnostic industry.
- Helix and Veracyte announced a partnership on August 7, 2025, to expand access to genomic insights.
- Marc Stapley was appointed as the chief executive officer of Veracyte on August 7, 2025.
- Veracyte reported that its earnings and revenue beat consensus estimates on August 12, 2025.
- Zacks highlighted Veracyte as a strong momentum stock on August 24, 2025.